3 mg [14C]-A4250 capsule
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Orphan Cholestatic Liver Diseases
Conditions
Orphan Cholestatic Liver Diseases, Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome, Primary Biliary Cirrhosis
Trial Timeline
Jan 31, 2017 → Mar 8, 2017
NCT ID
NCT03082937About 3 mg [14C]-A4250 capsule
3 mg [14C]-A4250 capsule is a phase 1 stage product being developed by Ipsen for Orphan Cholestatic Liver Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT03082937. Target conditions include Orphan Cholestatic Liver Diseases, Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03082937 | Phase 1 | Completed |
Competing Products
2 competing products in Orphan Cholestatic Liver Diseases
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Caffeine + Dextromethorphan + Enzalutamide + Enzalutamide Placebo to Match (PTM) | Astellas Pharma | Phase 1 | 33 |
| A4250 + CRC (A3384) + Questran + Placebo | Ipsen | Phase 1 | 30 |